drugset / Trial / NCT00689039

Study of an Extended Release (ER) Tablet, Single and Repeated Dosing

NCT00689039

Phase 1 Completed 94 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose is to study the safety and tolerability of increasing doses of AZD1305 and how the medication is metabolised by the body (how it is taken up, distributed, and how it disappears from the body). The study is performed in healthy volunteers.

Timeline

Start
2007-04
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1305 Small molecule Oral

Indications

No indication recorded.